Quantcast

Industry news that matters to you.  Learn more

Rosetta Genomics Signs Agreements to Advance Development of Body Fluids-Based Diagnostic Tests

Rosetta Genomics has announced that it has signed two new agreements for the development and validation of microRNA-based diagnostics for various indications related to its Gen 3 products. Rosetta Genomics Gen 3 tests focus on cardiovascular indications, neurodegenerative diseases, women’s health and early detection of certain cancers, and are designed to leverage microRNA biomarkers extracted from body fluids.